Arvinas (ARVN) Profit After Tax (2017 - 2026)
Arvinas' (ARVN) quarterly Profit After Tax came in at -$57.6 million in Q1 2026, down 169.06% year-on-year from $83.4 million in Q1 2025, and up 14.79% quarter-over-quarter from -$67.6 million in Q4 2025.
Arvinas (ARVN) Profit After Tax (2017 - 2026) Analysis & Trends
Arvinas' Profit After Tax history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 169.06% year-over-year to -$57.6 million in Q1 2026; TTM through Mar 2026 was -$221.1 million, a 488.03% decrease from a year earlier, with the FY2025 full-year figure at -$80.6 million, up 59.48% from the prior year.
- Profit After Tax grew to -$57.6 million in Q1 2026 per ARVN's latest filing, from -$67.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at $83.4 million in Q1 2025 and bottomed at -$138.7 million in Q4 2023.
- The 5-year median for Profit After Tax is -$62.7 million (2022), against an average of -$55.0 million.
- Across the five-year window, Profit After Tax jumped 220.17% in 2025 and tumbled 169.06% in 2026, its largest moves.
- Year by year, Profit After Tax stood at -$62.7 million in 2022, then plunged by 121.21% to -$138.7 million in 2023, then jumped by 67.48% to -$45.1 million in 2024, then slumped by 49.89% to -$67.6 million in 2025, then gained by 14.79% to -$57.6 million in 2026.
- Per Business Quant, the three latest ARVN Profit After Tax figures stand at -$57.6 million (Q1 2026), -$67.6 million (Q4 2025), and -$34.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - | -57.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.60 Mn |
| Sep 30, 2025 | -34.70 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 83.40 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -41.30 Mn |
| Jun 30, 2024 | -34.60 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -138.70 Mn |
| Sep 30, 2023 | -61.00 Mn |
| Jun 30, 2023 | -66.60 Mn |
| Mar 31, 2023 | -75.30 Mn |
| Dec 31, 2022 | -62.70 Mn |
| Sep 30, 2022 | -69.00 Mn |
| Jun 30, 2022 | -70.00 Mn |
| Mar 31, 2022 | -63.40 Mn |
| Dec 31, 2021 | -51.80 Mn |
| Sep 30, 2021 | -46.90 Mn |
| Jun 30, 2021 | -50.50 Mn |